Shopping Cart
Remove All
Your shopping cart is currently empty
Mirvetuximab soravtansine (Synonyms: TAK-853, IMGN-853, IMGN853)
Catalog No. T77825 Copy Product Info
Purity: 95%
🥰Excellent
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
Mirvetuximab soravtansine
Copy Product Info🥰Excellent
Catalog No. T77825
Synonyms TAK-853, IMGN-853, IMGN853
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
Mirvetuximab soravtansine
Cas No. 1453084-37-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $923 | - | In Stock | |
| 5 mg | $2,540 | - | In Stock | |
| 10 mg | $3,420 | - | In Stock | |
| 25 mg | $4,970 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.52% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer. |
| In vitro | 8 nM Mirvetuximab soravtansine in combination with Carboplatin treated IGROV-1 cells showed enhanced synergistic inhibition of growth and disruption of the cell cycle in vitro. [1] |
| In vivo | Intravenous injection of 5 mg/kg Mirvetuximab soravtansine enhances the antitumor effect of Carboplatin in vivo using a xenograft model derived from SCID female mouse patients. [1] |
| Synonyms | TAK-853, IMGN-853, IMGN853 |
| Reactivity | Human |
| Verified Activity | Immobilized Human FOLR1 Protein (His) (TMPY-01743) at 1 μg/mL (100 μL/well) can bind Mirvetuximab soravtansine. The EC50 is 3.66 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <10 EU/mg |
| Conjucates | DM4 |
| Gene ID | |
| Uniprot ID | |
| Target | FOLR1/FRA |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1453084-37-1 |
| Isotype | IgG1-DM4 |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Mirvetuximab soravtansine | purchase Mirvetuximab soravtansine | Mirvetuximab soravtansine cost | order Mirvetuximab soravtansine | Mirvetuximab soravtansine in vivo | Mirvetuximab soravtansine in vitro | Mirvetuximab soravtansine molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.